Patents by Inventor Leah Lynn Frye

Leah Lynn Frye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of bruton's tyrosine kinase
    Patent number: 9708326
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 18, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Shunqi Yan, David J. Loury, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Longcheng Wang
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 9580416
    Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk) having the structure of Formula (B): Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 28, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Shunqi Yan, David J. Loury, Zhaozhong J. Jia, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Gordana Babic Atallah, Riccardo Zanaletti, Maria Pia Catalani, Luca Francesco Raveglia
  • Purinone compounds as kinase inhibitors
    Patent number: 9469642
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: October 18, 2016
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Shunqi Yan, Longcheng Wang, Leah Lynn Frye
  • IRAK INHIBITORS AND USES THEREOF
    Publication number: 20160296524
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 13, 2016
    Inventors: Donna L. Romero, Matthew David Wessel, Shaughnessy Robinson, Jeremy Robert Greenwood, Karl Shawn Watts, Leah Lynn Frye, Geraldine C. Harriman, Alan Franklin Corin, Craig E. Masse, Mee Shelley
  • IRAK inhibitors and uses thereof
    Patent number: 9340554
    Abstract: The present invention provides 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine compounds and pharmaceutical compositions thereof as inhibitors of IRAK.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: May 17, 2016
    Assignee: NIMBUS IRIS, INC.
    Inventors: Donna L. Romero, Matthew David Wessel, Shaughnessy Robinson, Jeremy Robert Greenwood, Karl Shawn Watts, Leah Lynn Frye, Geraldine C. Harriman, Alan Franklin Corin, Craig E. Masse, Mee Shelley
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20160002225
    Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Inventors: Wei CHEN, Longcheng WANG, Shunqi YAN, David J. LOURY, Zhaozhong J. JIA, Leah Lynn FRYE, Jeremy Robert GREENWOOD, Mee Yoo SHELLEY, Gordana Babic ATALLAH, Riccardo ZANALETTI, Maria Pia CATALANI, Luca Francesco RAVEGLIA
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20160002241
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 7, 2016
    Applicant: PHARMACYCLICS, LLC.
    Inventors: Wei CHEN, Shunqi YAN, David J. LOURY, Leah Lynn FRYE, Jeremy Robert GREENWOOD, Mee Yoo SHELLEY, Longcheng WANG
  • IRAK INHIBITORS AND USES THEREOF
    Publication number: 20150025093
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: February 25, 2014
    Publication date: January 22, 2015
    Applicant: Nimbus Iris, Inc.
    Inventors: Donna L. Romero, Matthew David Wessel, Shaughnessy Robinson, Jeremy Robert Greenwood, Karl Shawn Watts, Leah Lynn Frye, Geraldine C. Harriman, Alan Franklin Corin, Craig E. Masse, Mee Shelley
  • PURINONE COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20140378446
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 30, 2013
    Publication date: December 25, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Yan Shunqi, Longcheng Wang, Leah Lynn Frye
  • IRAK inhibitors and uses thereof
    Patent number: 8703941
    Abstract: The present invention provides thienopyrimidine and thienopyridine compounds, compositions thereof, and methods of using the same for the treatment of diseases mediated by IRAK enzymes. Such diseases include inflammatory and proliferative diseases.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: April 22, 2014
    Assignee: Nimbus Iris, Inc.
    Inventors: Donna L. Romero, Matthew David Wessel, Shaughnessy Robinson, Jeremy Robert Greenwood, Karl Shawn Watts, Leah Lynn Frye, Geraldine C. Harriman, Alan Franklin Corin, Craig E. Masse, Mee Shelley
  • IRAK INHIBITORS AND USES THEREOF
    Publication number: 20120283238
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: January 10, 2012
    Publication date: November 8, 2012
    Applicant: NIMBUS IRIS, INC.
    Inventors: Donna L. Romero, Matthew David Wessel, Shaughnessy Robinson, Jeremy Robert Greenwood, Karl Shawn Watts, Leah Lynn Frye, Geraldine C. Harriman, Alan Franklin Corin, Craig E. Masse
  • 1-phenylpydrrolidin-2-ones and -thiones and 1-(4-pyridyl)pydrrolidin-2-ones and -thiones which are useful in the treatment of inflammatory disease
    Patent number: 6414153
    Abstract: Novel compounds of the formula I: which are useful for treating or preventing inflammatory and immune cell-mediated diseases. Exemplary compounds are: 3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-1,3-dihydroindol-2-one; 3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-3-methyl-1,3-dihydro-indol-2-one; 3-benzyl-1-(3,5-dichlorophenyl)-3-methyl-1,3-dihydroindol-2-one; 3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-4-hydroxy-3-methyl-1,3-dihydroindol-2-one; and, 3-(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-fluoro-1,3-dihydroindol-2-one.
    Type: Grant
    Filed: June 28, 2000
    Date of Patent: July 2, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence Alfred Kelly, Jiang-Ping Wu, Daniel Kuzmich, Yancey David Ward, Leah Lynn Frye
  • Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
    Patent number: 6355664
    Abstract: A method treating or preventing inflammatory and immune cell-mediated diseases by the administration of certain novel and known small molecules.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: March 12, 2002
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence A. Kelly, Barbara Jean Bormann, Leah Lynn Frye, Jiang-Ping Wu
  • Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
    Patent number: RE38132
    Abstract: A method treating or preventing inflammatory and immune cell-mediated diseases by the administration of certain novel and known small molecules.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: June 3, 2003
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Terence A. Kelly, Barbara Jean Bormann, Leah Lynn Frye, Jiang-Ping Wu